Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis

CT-P13 is an infliximab biosimilar approved for indications including ankylosing spondylitis (AS); the approved maintenance regimen is 5 mg/kg infused every 6–8 weeks. In clinical practice, modifications to infliximab dose and/or infusion interval can be beneficial to the patient. For CT-P13, real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shin-Seok, Kim, Tae-Hwan, Park, Won, Song, Yeong-Wook, Suh, Chang-Hee, Kim, Soo-Kyoung, Yoo, Dae-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509762/
https://www.ncbi.nlm.nih.gov/pubmed/34640586
http://dx.doi.org/10.3390/jcm10194568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509762/
https://www.ncbi.nlm.nih.gov/pubmed/34640586
http://dx.doi.org/10.3390/jcm10194568

Ejemplares similares